Clinical trial · Interventional
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
NCT02297139CI-TRIAL-00066155completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Indications Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dasatinib | Drug | Dasatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dasatinib
- description
- This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
- interventionNames
- Drug: Dasatinib
Primary outcomes (2)
- measure
- Number of Participants Who Received Dasatinib Treatment
- timeFrame
- From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)
- description
- Number of participants who received dasatinib treatment for prostate cancer and chronic phase chronic myeloid leukemia who had also participated on prior protocols CA180-227, CA180-363 and CA180-056 investigating dasatinib. Dasatinib tablet administered once a day by mouth.
- measure
- Duration of Treatment
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol * Receiving dasatinib at the time of signature of informed consent * Males and Females, ages 18 and older Exclusion Criteria: * All patients previously discontinued from a dasatinib study for any reason * Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy * History of allergy to dasatinib
References
Publications (0)
Data not yet available
No reference posted for this study.